Award
National Cancer Institute 5R01CA281286-04
Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer
Recipient
University of California, San Diego
Award Amount
$618,271.00
Ceiling
$618,271.00
Awarded
July 30, 2026
Identifier
5R01CA281286-04
A phase IIb clinical trial aiming to enhance response to PD-1 inhibitor immunotherapy in HPV-related oropharynx cancer by combining stereotactic body radiation with anti-CD47 and anti-PD-1 therapies, targeting improved pathologic response and cancer immunosurveillance.
Description
This project focuses on improving immunotherapy responses in HPV-related oropharyngeal cancers through targeted radiation and combination immunotherapy, with a goal of achieving high pathologic response rates and better quality of life outcomes.